Literature DB >> 24125120

Analytical performance, agreement and user-friendliness of five C-reactive protein point-of-care tests.

Margaretha C Minnaard1, Alma C van de Pol, Berna D L Broekhuizen, Theo J M Verheij, Rogier M Hopstaken, Sanne van Delft, Antoinette M J Kooijman-Buiting, Joris A H de Groot, Niek J De Wit.   

Abstract

BACKGROUND: Point-of-care (POC) C-reactive protein (CRP) testing is increasingly used in primary care to assist general practitioners (GPs) in the diagnostic workup for various complaints. The present study compares analytical performance, agreement and user-friendliness of five of these POC CRP tests.
METHODS: The following five POC CRP tests were evaluated: Afinion and NycoCard Reader II (both Alere), Eurolyser Smart 700/340 (Eurolyser), QuikRead go and QuikRead 101 (both Orion Diagnostica). Results were compared with those of a standard immunoturbidimetric method performed on a routine analyzer (Olympus AU 2700, Beckman Coulter). Analytical performance and agreement with the laboratory standard for the five different POC tests were analyzed. Subsequently, user-friendliness of the POC tests was assessed.
RESULTS: Within-day CVs varied from 2.6% (QuikRead go) to 19.4% (Eurolyser Smart 700/340) for low CRP values (< 20 mg/L), and 1.1% (QuikRead go) to 17.5% (Eurolyser Smart 700/340) for high values (> 100 mg/L). Between-day CVs varied from 4.6% (Afinion) to 30.5% (Eurolyser Smart 700/340) for low values and 4.0% (QuikRead go) to 18.0% (Eurolyser Smart 700/340) for high values. With high CRP values (> 100 mg/L) agreement with the laboratory standard systematically decreased for all POC tests. Regarding user-friendliness Afinion and Eurolyser Smart 700/340 were judged easiest to operate.
CONCLUSIONS: Analytical performance, agreement, and user-friendliness of the POC CRP tests varied considerably, yet overall four devices showed adequate analytical performance and agreement.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24125120     DOI: 10.3109/00365513.2013.841985

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  9 in total

1.  The added value of C-reactive protein measurement in diagnosing pneumonia in primary care: a meta-analysis of individual patient data.

Authors:  Margaretha C Minnaard; Joris A H de Groot; Rogier M Hopstaken; Alwin Schierenberg; Niek J de Wit; Johannes B Reitsma; Berna D L Broekhuizen; Saskia F van Vugt; Arie Knuistingh Neven; Aleida W Graffelman; Hasse Melbye; Timothy H Rainer; Johann Steurer; Anette Holm; Ralph Gonzales; Geert-Jan Dinant; Alma C van de Pol; Theo J M Verheij
Journal:  CMAJ       Date:  2016-09-19       Impact factor: 8.262

2.  Implementation factor mapping of a pilot study of point-of-care C-reactive protein testing for respiratory tract infections in community pharmacy.

Authors:  Leanne Chalmers; Petra Czarniak; Jeffery Hughes; Rebecca Iacob; Ya Ping Lee; Kiran Parsons; Richard Parsons; Bruce Sunderland; Tin Fei Sim
Journal:  Explor Res Clin Soc Pharm       Date:  2022-06-02

3.  Analytical performance of a platform for point-of-care CRP testing in adults consulting for lower respiratory tract infection in primary care.

Authors:  Veerle Matheeussen; Viviane Van Hoof; Katherine Loens; Christine Lammens; Anouk Vanderstraeten; Samuel Coenen; Chris C Butler; Paul Little; Theo J M Verheij; Herman Goossens; Margareta Ieven
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-10       Impact factor: 3.267

4.  Should all acutely ill children in primary care be tested with point-of-care CRP: a cluster randomised trial.

Authors:  Jan Y Verbakel; Marieke B Lemiengre; Tine De Burghgraeve; An De Sutter; Bert Aertgeerts; Bethany Shinkins; Rafael Perera; David Mant; Ann Van den Bruel; Frank Buntinx
Journal:  BMC Med       Date:  2016-10-06       Impact factor: 8.775

5.  Using point-of-care C-reactive protein to guide antibiotic prescribing for lower respiratory tract infections in elderly nursing home residents (UPCARE): study design of a cluster randomized controlled trial.

Authors:  Tjarda M Boere; Laura W van Buul; Rogier M Hopstaken; Ruth B Veenhuizen; Maurits W van Tulder; Jochen W L Cals; Theo J M Verheij; Cees M P M Hertogh
Journal:  BMC Health Serv Res       Date:  2020-02-27       Impact factor: 2.655

6.  Economic considerations support C-reactive protein testing alongside malaria rapid diagnostic tests to guide antimicrobial therapy for patients with febrile illness in settings with low malaria endemicity.

Authors:  Yoel Lubell; Arjun Chandna; Frank Smithuis; Lisa White; Heiman F L Wertheim; Maël Redard-Jacot; Zachary Katz; Arjen Dondorp; Nicholas Day; Nicholas White; Sabine Dittrich
Journal:  Malar J       Date:  2019-12-26       Impact factor: 2.979

7.  Antibiotic prescribing rate after optimal near-patient C-reactive protein testing in acutely ill children presenting to ambulatory care (ARON project): protocol for a cluster-randomized pragmatic trial.

Authors:  Jan Yvan Jos Verbakel; Tine De Burghgraeve; Ann Van den Bruel; Samuel Coenen; Sibyl Anthierens; Louise Joly; Annouschka Laenen; Jeroen Luyten; An De Sutter
Journal:  BMJ Open       Date:  2022-01-03       Impact factor: 2.692

8.  Performance of C-reactive protein and procalcitonin to distinguish viral from bacterial and malarial causes of fever in Southeast Asia.

Authors:  Yoel Lubell; Stuart D Blacksell; Susanna Dunachie; Ampai Tanganuchitcharnchai; Thomas Althaus; Wanitda Watthanaworawit; Daniel H Paris; Mayfong Mayxay; Thomas J Peto; Arjen M Dondorp; Nicholas J White; Nicholas P J Day; François Nosten; Paul N Newton; Paul Turner
Journal:  BMC Infect Dis       Date:  2015-11-11       Impact factor: 3.090

9.  Accuracy of commercially available c-reactive protein rapid tests in the context of undifferentiated fevers in rural Laos.

Authors:  Koukeo Phommasone; Thomas Althaus; Phonesavanh Souvanthong; Khansoudaphone Phakhounthong; Laxoy Soyvienvong; Phatthaphone Malapheth; Mayfong Mayxay; Rebecca L Pavlicek; Daniel H Paris; David Dance; Paul Newton; Yoel Lubell
Journal:  BMC Infect Dis       Date:  2016-02-04       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.